The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study.
about
Chemotherapy for advanced non-small cell lung cancer in the elderly populationChemotherapy for non-small cell lung cancer in the elderly populationOral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancerEpidemiology and management of common pulmonary diseases in older personsPemetrexed versus vinorelbine treatment of advanced non-squamous non-small cell lung cancer in elderly patientsA phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trialsAdverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancerTreatment of advanced non small cell lung cancer in routine care: a retrospective analysis of 212 consecutive patients treated in a community based oncology group practiceThe treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approachGeriatric oncology: an overview of progresses and challenges.Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial.A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer.Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases.The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studiesSurvival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba.A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.Gemcitabine Plus Platinum Combination Chemotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Analysis.Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.Five years managing metastatic non-small cell lung cancer: experience at a teaching hospital.Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib.Treatment Toxicity in Elderly Patients With Advanced Non-Small Cell Lung Cancer.Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans.Senior adult oncology.Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.Therapeutic strategy for treatment of metastatic non-small cell lung cancer.Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.Current challenges of lung cancer care in an aging population.Tubulin inhibitors in non-small cell lung cancer: looking back and forward.Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer.Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung CancerProspective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer.Recent advances in targeted advanced lung cancer therapy in the elderly.[Clinicopathologic Characteristics of the Patients in the Elderly Lung Carcinoma].Methods of preventing vinorelbine-induced phlebitis: an experimental study in rabbits.First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?Chemotherapy for advanced non-small-cell lung cancer patients with poor performance.
P2860
Q24186466-81B8D2C2-7ECF-4812-8B2A-3B17E4BA672CQ24200434-27E4286A-D6DC-458D-A418-688C26193F2EQ26752937-B8F62503-13FC-4F45-A746-FEB6C62E1B35Q28397465-80BE41D1-1060-4270-87D0-10A02CBB74D4Q33414072-6B27AC0B-6B85-481F-AE54-43D1D78E130FQ33427832-BADCD9DB-685D-408D-9644-EE93FF5B4760Q33436415-B7C1292D-4CCB-48DD-A029-A858916FCD68Q33628784-C4DA71CB-3ED3-4F9D-9634-9C3C2E21ED9EQ33860259-171F0121-B69B-4F5B-A62C-CA22CD535705Q33878770-65870F15-B0D9-4D7C-931B-997EC2301278Q33979972-D53244A3-8DCE-4FBF-8935-BCE89C7E7EC4Q34276419-A71891A3-561F-45C6-9DDA-D26731E6C883Q34433040-FB654DB9-6B7D-4C25-ACB4-DEC4927A06ADQ34563336-E8B985A2-B779-4DC2-9047-C28592EA871FQ34791240-97218329-3EA2-4777-9085-39ED9D1B4C6DQ35073353-BB8CCE5F-0702-4107-9CDF-A4BEF1251B6CQ35262406-873121DB-F1CC-4663-AB4A-B76CD4AD4E25Q35653167-E3719483-39A0-41F4-888A-6D8950810BD2Q35661049-4008A6A9-1034-45D8-A63E-EA068A430F68Q35820508-E5D905B9-6D29-4B74-AA6A-A5A222ED6BE5Q35866141-DBE8D8BA-3B93-4548-B3A2-B549D29CC8E5Q35875986-2D865D30-0BAE-422F-81F5-715B680DF9E7Q36055304-CE8BE5DF-77B3-45DD-B7BA-0F3BEC99E9C5Q36058277-8322BA33-C30F-4909-9747-8E0667577FC8Q36851424-2BE20665-58C5-4D73-A6E6-A7F75210E594Q36924607-284E1D01-6E74-483D-8000-1CE1F12D53E0Q37310694-B738A909-5A10-43E0-B5A0-917C0871ED01Q37509502-63884F0F-A6EE-489C-9C19-C6A907E18A3CQ38601725-F9DFE30A-CAFD-47F6-9323-C672FB398FBBQ38608627-3BB4A621-7B8E-4522-84EA-56EF3B886AEAQ38742506-E72C3AF2-B297-4203-A73D-082118AE5E85Q38760512-FFCA9402-0A0E-418E-B6CA-E67C0A073534Q38847914-38E23328-5AAD-4C04-86E3-D497F52CFC71Q38938753-6A765D9B-B937-4656-930E-FFE8957B3332Q39470697-1A544D82-8063-48D0-BF76-3C42EA544F2DQ40143039-BE0C84AF-BC0F-45C7-AE11-787FFC20551BQ40530440-23D0C78C-FD8A-44AC-A5A9-032076FABA32Q41555214-88CCA95D-BCAD-4213-913C-BDB4141032D9Q41860438-93B12AEF-81F6-43B4-9697-5AD015431342Q42723608-C75A0E9A-B4A4-48C7-85F4-C69F3F696E72
P2860
The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The ELVIS trial: a phase III s ...... cer Vinorelbine Italian Study.
@ast
The ELVIS trial: a phase III s ...... cer Vinorelbine Italian Study.
@en
type
label
The ELVIS trial: a phase III s ...... cer Vinorelbine Italian Study.
@ast
The ELVIS trial: a phase III s ...... cer Vinorelbine Italian Study.
@en
prefLabel
The ELVIS trial: a phase III s ...... cer Vinorelbine Italian Study.
@ast
The ELVIS trial: a phase III s ...... cer Vinorelbine Italian Study.
@en
P921
P1433
P1476
The ELVIS trial: a phase III s ...... cer Vinorelbine Italian Study.
@en
P2093
Gridelli C
P356
10.1634/THEONCOLOGIST.6-SUPPL_1-4
P478
P577
2001-01-01T00:00:00Z